Takeda Ventures

hC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA. Their First in Class approach for protein editing advances beyond genome editing to direct modification of the proteome.

Integra Therapeutics is focused on advancing gene editing technologies to address various diseases. The company is developing innovative gene writing tools that aim to enhance the effectiveness of gene therapy. By combining the precision of CRISPR systems with the efficiency of viral integrases and transposases, Integra Therapeutics seeks to overcome existing limitations in the field of gene editing. This approach allows scientists to introduce DNA into a genome using sequence-specific DNA binding proteins, thereby facilitating the development of targeted gene therapies that meet the specific needs of patients.

Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.

BridGene Biosciences is a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules. It enables covalent small molecules to perform proteome-wide screening in live cells, which results in highly selective small molecules that drug traditionally undruggable targets.

Seqster, PDM Inc. develops a software-as-a-service (SaaS) that allows the members, payers, providers, clinical research enterprise employees, foundations, and patients to import medical data from electronic health records (EHR), genetic, and fitness data from various sources. It offers Seqster, a health data management solution to collect users' EHR, DNA, and wearables data, enabling its customers to collect, own, and share their health information on their terms. The company was founded in 2016 and is based in San Diego, California.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The Company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, specializing in the development of adeno-associated viral (AAV) vector technologies and therapeutics aimed at treating rare diseases. Founded in 2015, the company employs a unique STRucture Inspired DEsign approach that merges structural knowledge with accelerated evolution to create innovative AAV capsids. This technology is designed to evade neutralizing antibodies, thereby enhancing gene transfer efficiency. StrideBio's platform supports various gene therapy modalities, including gene addition, gene silencing, and gene editing, with applications across a range of rare genetic disorders.

Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.

Redpin Therapeutics, Inc., gene therapy company, develops a chemo genetics platform for targeted cell therapies that address intractable diseases of the nervous system. It discovers and develops an ion channel-based chemo genetics platform that enables targeted cell activation/inhibition controlled by low doses of the anti-smoking drug Varenicline. Redpin Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.

Seqster, PDM Inc. develops a software-as-a-service (SaaS) that allows the members, payers, providers, clinical research enterprise employees, foundations, and patients to import medical data from electronic health records (EHR), genetic, and fitness data from various sources. It offers Seqster, a health data management solution to collect users' EHR, DNA, and wearables data, enabling its customers to collect, own, and share their health information on their terms. The company was founded in 2016 and is based in San Diego, California.

Emendo Bio, Inc. is a biotechnology company focused on developing innovative genome editing technologies aimed at repairing and eliminating genetic mutations responsible for serious diseases and disorders. Founded in 2015 and headquartered in New York, the company integrates expertise in protein engineering, DNA repair, and computational analysis to advance its gene editing capabilities. Emendo Bio is dedicated to creating genetic medicines that address currently untreatable conditions by transforming existing tools and methodologies. The company operates as a subsidiary of AnGes, Inc., emphasizing a collaborative approach that combines knowledge from diverse scientific disciplines to overcome challenges in the field of gene therapy. Through its cutting-edge research, Emendo Bio aims to push the boundaries of what is possible in the realm of genetic medicine.

Avidity Biosciences is a biopharmaceutical company specializing in the development of oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. Avidity's lead product candidate, AOC 1001, targets myotonic dystrophy type 1, a rare genetic muscle disorder. The company's development pipeline also includes programs focused on treating various muscle diseases, such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Additionally, Avidity is exploring therapeutic applications for immune and other cell types, leveraging its proprietary AOC platform to reach previously undruggable tissues and effectively target the genetic underpinnings of these conditions. Founded in 2012, Avidity Biosciences is headquartered in La Jolla, California.

Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.

Avidity Biosciences is a biopharmaceutical company specializing in the development of oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. Avidity's lead product candidate, AOC 1001, targets myotonic dystrophy type 1, a rare genetic muscle disorder. The company's development pipeline also includes programs focused on treating various muscle diseases, such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Additionally, Avidity is exploring therapeutic applications for immune and other cell types, leveraging its proprietary AOC platform to reach previously undruggable tissues and effectively target the genetic underpinnings of these conditions. Founded in 2012, Avidity Biosciences is headquartered in La Jolla, California.

Reborna Biosciences Inc is a biotechnology company based in Fujisawa, Japan, focused on research and development in genetic diseases. The company aims to address unmet medical needs by developing therapeutic options for rare genetic disorders. Utilizing innovative technology, Reborna Biosciences creates low-molecular compounds designed to target ribonucleic acid, leading to the development of new disease-modifying drugs. Among its key therapeutic areas is spinal muscular atrophy, a rare genetic disease for which the company seeks to provide effective treatments.

StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, specializing in the development of adeno-associated viral (AAV) vector technologies and therapeutics aimed at treating rare diseases. Founded in 2015, the company employs a unique STRucture Inspired DEsign approach that merges structural knowledge with accelerated evolution to create innovative AAV capsids. This technology is designed to evade neutralizing antibodies, thereby enhancing gene transfer efficiency. StrideBio's platform supports various gene therapy modalities, including gene addition, gene silencing, and gene editing, with applications across a range of rare genetic disorders.

WaVe Life Sciences Ltd. is a clinical stage genetic medicine company focused on developing novel stereopure oligonucleotides through its proprietary PRISM platform. The company aims to address genetic defects by either reducing the expression of harmful proteins or converting dysfunctional mutant proteins into functional ones. It primarily concentrates on neurological disorders affecting the central and neuromuscular systems. WaVe Life Sciences has established research and collaboration agreements with major pharmaceutical companies to advance its oligonucleotide therapeutics. Founded in 2012, the company is headquartered in Singapore and maintains research facilities in Boston and Japan. The organization was established by leading scientists in the field of chemistry and life sciences, underscoring its commitment to innovative approaches in nucleic acid therapeutics.

Ultragenyx Pharmaceutical is a biopharmaceutical company based in the United States that focuses on developing therapeutics for rare and ultra-rare diseases, particularly serious genetic conditions. The company identifies, acquires, and commercializes novel treatments, leveraging existing scientific knowledge to address unmet medical needs in this challenging area. Its portfolio includes several medicines such as Crysvita, which treats X-linked hypophosphatemia in both adults and pediatric patients, Dojolvi, and Mepsevii, indicated for Mucopolysaccharidosis VII. Ultragenyx aims to create impactful therapeutics by employing effective development strategies tailored to the complexities of rare diseases.

Seattle Genetics is a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.

ArmaGen, Inc. is a clinical stage biotechnology company that develops therapies to treat severe neurological diseases. The company focuses on therapies for lysosomal storage, hunter syndrome, hurler syndrome, Sanfilippo A syndrome, metachromatic leukodystrophy, and neurodegenerative diseases. Its product candidates include AGT-182 for hunter syndrome; and AGT-181 for hurler syndrome. The company was formerly known as ArmaGen Technologies, Inc. ArmaGen, Inc. was incorporated in 2001 and is headquartered in San Diego, California.

Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. Its innovative pipeline targets a range of serious conditions, including genetic disorders, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system and ocular diseases. The company has successfully brought several RNAi therapeutics to market, including ONPATTRO for hereditary transthyretin-mediated amyloidosis and GIVLAARI for acute hepatic porphyria. Additionally, Alnylam is advancing other investigational therapies, such as givosiran for acute hepatic porphyria and lumasiran for primary hyperoxaluria type 1. The company collaborates with various partners, including Sanofi Genzyme and Vir Biotechnology, to enhance its research and development efforts. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals aims to transform treatment approaches for patients with rare and debilitating diseases through its RNAi technology.

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Burnaby, Canada, focused on developing innovative therapeutics for neurological disorders. The company's clinical pipeline includes several product candidates targeting epilepsy, such as XEN496 and XEN1101, both Kv7 potassium channel modulators currently in Phase II trials, and XEN901, a selective Nav1.6 sodium channel inhibitor in Phase I trials. Additionally, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase I trials. Xenon utilizes a proprietary discovery platform, known as Extreme Genetics, to identify genetic insights from families with severe phenotypes, enabling the development of novel medicines for both orphan and more common diseases. The company has established a collaboration with Neurocrine Biosciences to advance first-in-class treatments for epilepsy, highlighting its commitment to addressing unmet medical needs in the field of neurology.